NCCN 2015 Congress Series™: Melanoma

Jacksonville, FL US
November 7, 2015

Clinicians need to be aware of the treatment and management of melanoma across the continuum of care. As the armamentarium against advanced melanoma continues to expand, clinicians need to be informed on how to select the most appropriate therapy for each patient and to carefully monitor the unique side effects. Since there is a lack of consensus on the optimal treatment for stage III disease, clinicians need to be educated on the pros and cons of each strategy. A thorough pathology report of the primary melanoma lesion at diagnosis must not be overlooked as it forms a critical basis for prognosis prediction and treatment decisions.

This educational initiative addresses health care professionals’ need to be educated on current and emerging evidence-based scientific data for accurate and timely clinical evaluation of patients with melanoma and related skin cancers, management of both early- and late-stage diseases, and advanced cancer.

Target Audience

This educational program is designed to meet the educational needs of oncologists, nurses, pharmacists, dermatologists, and other health care professionals who manage patients with melanoma and related skin cancers.

Learning Objectives

Following this activity, participants should be able to:

Characteristics of a Pathology Report

  • List essential tumor characteristics that should be included in the pathology report at initial melanoma diagnosis
  • Outline additional pathologic factors that have prognostic or predictive value

Surgical Management of Localized Melanoma

  • Describe different types of biopsy techniques for melanoma
  • Summarize data on surgical margins for excising primary melanoma lesions

Systemic Therapies for Advanced Melanoma

  • Compare PD-1-targeted immunotherapy with ipilimumab
  • Explain the clinical data demonstrating the benefits of combining BRAF-MEK-targeted agents compared to monotherapy

Recognition and Management of Toxicities

  • Identify immune-related adverse events that can occur with the use of immunotherapy and recommend appropriate monitoring and management
  • Counsel patients on the toxicity profile of BRAF-targeted agents
Additional information

Supported by an educational donation provided by Amgen.

Supported by educational grants from:

  • Bristol-Myers Squibb
  • Merck
  • Prometheus Laboratories Inc.
Course summary
Available credit: 
  • 3.00 Participation
  • 3.00 Nurse
  • 3.00 Pharmacist
  • 3.00 Physician
Course opens: 
Course expires: 
Event starts: 
11/07/2015 - 8:00am EST
Event ends: 
11/07/2015 - 12:00pm EST
Mayo Clinic Cancer Center - Jacksonville
4500 San Pablo Road
Walker Auditorium
Jacksonville, FL 32224
United States

This activity is approved for AMA PRA Category 1 Credit(s)™ for physicians and is also accredited for nurses and pharmacists. View complete accreditation details

Available Credit

  • 3.00 Participation
  • 3.00 Nurse
  • 3.00 Pharmacist
  • 3.00 Physician


Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
  • Adobe Reader or other PDF reader software for certificate viewing/printing